Kennedy Capital Management’s Avadel Pharmaceuticals AVDL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-1,194,197
| Closed | -$25.7M | – | 538 |
|
|
2025
Q4 | $25.7M | Sell |
1,194,197
-432,621
| -27% | -$8.4M | 0.55% | 27 |
|
|
2025
Q3 | $24.8M | Buy |
1,626,818
+645,547
| +66% | +$8.4M | 0.55% | 26 |
|
|
2025
Q2 | $8.68M | Buy |
981,271
+227,228
| +30% | +$2M | 0.21% | 169 |
|
|
2025
Q1 | $5.9M | Sell |
754,043
-302,891
| -29% | -$2.54M | 0.14% | 252 |
|
|
2024
Q4 | $11.1M | Buy |
1,056,934
+468,757
| +80% | +$5.69M | 0.25% | 121 |
|
|
2024
Q3 | $7.71M | Sell |
588,177
-65,939
| -10% | -$1M | 0.17% | 212 |
|
|
2024
Q2 | $9.2M | Buy |
654,116
+969
| +0.1% | +$15.8K | 0.2% | 173 |
|
|
2024
Q1 | $11M | Buy |
653,147
+7,273
| +1% | +$108K | 0.23% | 150 |
|
|
2023
Q4 | $9.12M | Sell |
645,874
-69,550
| -10% | -$817K | 0.2% | 190 |
|
|
2023
Q3 | $7.37M | Buy |
715,424
+268,704
| +60% | +$3.6M | 0.18% | 208 |
|
|
2023
Q2 | $7.36M | Buy |
446,720
+25,463
| +6% | +$331K | 0.17% | 224 |
|
|
2023
Q1 | $3.86M | Buy |
+421,257
| New | +$3.46M | 0.11% | 303 |
|
|
2016
Q1 | – | Sell |
-521,553
| Closed | -$6.37M | – | 730 |
|
|
2015
Q4 | $6.37M | Sell |
521,553
-892,314
| -63% | -$13.9M | 0.13% | 289 |
|
|
2015
Q3 | $23.1M | Sell |
1,413,867
-302,563
| -18% | -$6.66M | 0.47% | 27 |
|
|
2015
Q2 | $36.4M | Buy |
1,716,430
+272,400
| +19% | +$4.88M | 0.65% | 2 |
|
|
2015
Q1 | $26M | Buy |
1,444,030
+236,620
| +20% | +$3.7M | 0.45% | 31 |
|
|
2014
Q4 | $20.7M | Buy |
1,207,410
+175,172
| +17% | +$2.5M | 0.38% | 42 |
|
|
2014
Q3 | $14.8M | Buy |
1,032,238
+307,628
| +42% | +$4.42M | 0.29% | 77 |
|
|
2014
Q2 | $10.9M | Buy |
724,610
+277,114
| +62% | +$3.34M | 0.2% | 169 |
|
|
2014
Q1 | $6M | Buy |
+447,496
| New | +$4.8M | 0.11% | 333 |
|
Other funds holding AVDL
Kennedy Capital Management's AVDL Position: Q1 2026 in Review
Kennedy Capital Management sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 1,194,197 shares — an estimated $25.7M sold.
Kennedy Capital Management first reported a position in AVDL in Q1 2014 and held it in 20 quarters. The position peaked at $36.4M in Q2 2015. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.
- Kennedy Capital Management reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Kennedy Capital Management sold 1,194,197 Avadel Pharmaceuticals shares in Q1 2026, an estimated $25.7M.
- Kennedy Capital Management first reported a position in Avadel Pharmaceuticals in Q1 2014 and held it in 20 quarters.
- Kennedy Capital Management's Avadel Pharmaceuticals position peaked at $36.4M in Q2 2015.
- 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.
Based on Kennedy Capital Management's 13F filing for Q1 2026, filed 13 May 2026.